CD33-Targeted CAR-T Cells for AML Relapse Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for acute myeloid leukemia (AML) show limited efficacy and high relapse rates, with existing treatments like gemtuzumab ozogamicin providing only modest improvements in overall survival, highlighting the need for more potent targeting of CD33-expressing cells.
Innovation Solution
Engineered T cells with a chimeric antigen receptor (CAR) specifically targeting CD33, comprising an ectodomain that binds to CD33, a disrupted T cell receptor alpha chain constant region (TRAC) gene, and a disrupted beta-2-microglobulin (β2M) gene, equipped with a CD8 transmembrane domain, 41BB co-stimulatory domain, and CD3ζ co-stimulatory domain, are developed using CRISPR/Cas9 gene editing to enhance specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gemtuzumab ozogamicin (GO) is used to target CD33-expressing cells, then some therapeutic effect is achieved, but the overall survival improvement is only modest
Solution Approach 1:
The patent changes the payload parameter from the calicheamicin in GO to more potent cytotoxic agents including radiolabeled isotopes (Y-90, Zr-89), auristatins, and maytansinoids. This parameter change in the therapeutic agent's potency directly addresses the modest survival improvement limitation of GO while maintaining CD33 targeting
Solution Approach 2:
The patent creates composite therapeutic structures by combining CD33-targeting antibodies (such as hCD33 Ab, 8D10, 1F9) with various potent payloads including radioisotopes, cytotoxic drugs, and immunogenic cell death inducers. These composite antibody-drug conjugates and radiopharmaceuticals achieve both specific targeting and enhanced therapeutic effect, overcoming the limited efficacy of previous single-modality approaches
2Productivity
If standard induction chemotherapy is used to treat AML, then initial response is high, but relapse is common and prognosis remains poor
Solution Approach 1:
The patent employs CAR-T cells engineered with pre-activated cytotoxic receptors that immediately upon infusion can recognize and eliminate CD33+ leukemic cells without requiring prior activation signals. The CAR construct includes pre-configured co-stimulatory domains (CD28, 4-1BB) and cytotoxic domains (CD3ζ) that enable immediate tumor cell killing, providing preliminary therapeutic action that prevents relapse
Solution Approach 2:
The CAR-T cells are engineered to be self-sufficient therapeutic agents that autonomously seek out, recognize, and eliminate CD33+ leukemia cells without requiring external activation or support. The cells express endogenous TCR and signaling components necessary for autonomous anti-tumor activity, providing self-service therapy that maintains long-term remission
Data Source
AI summary
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as CD33+ malignancies.